Grifols Diagnostic Solutions Inc.February 17, 2022

FDA 483 - Grifols Diagnostic Solutions Inc. - February 17, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Grifols Diagnostic Solutions Inc.

Record Details

An FDA inspection of Grifols Diagnostic Solutions Inc. in San Diego, CA, a licensed device/IVD establishment, revealed two significant observations. The firm failed to promptly review, evaluate, and investigate complaints for MDR-reportable events, with technical support staff providing insufficient detail for safety assessments. Additionally, procedures for design changes were found to be inadequately established, specifically concerning the risk assessment for extended onboard stability of licensed test kits and analyzer software.

Company: Grifols Diagnostic Solutions Inc.
Inspection Date: February 17, 2022
Product Type: Device
Office: Division of Pharmaceutical Quality Operations IV
People: Lauren M. Lilly (Compliance Officer at FDA)
Linda Thai (Team Biologics Staff)
Gene D. Arcy

Open in Dashboard

ID · 00121337-e0dc-4230-baae-455a0d692b81